Literature DB >> 33711042

Application of mosaicism ratio to multifetal gestations.

Jill Rafalko1, Samantha Caldwell1, Erica Soster1, Eyad Almasri1, Graham McLennan1, Tong Liu1, Vivian Weinblatt1, Philip Cacheris1, Ron McCullough1.   

Abstract

Mosaicism ratio, or MR, is a laboratory metric that can be calculated using massively parallel sequencing data from cell-free DNA (cfDNA) screening. MR compares the amount of cfDNA present from a particular chromosome or chromosomal region to the overall fetal fraction of the specimen. In singleton gestations, MR may be used to refine the positive predictive value of an abnormal cfDNA screening result by identifying cases that could be impacted by various biological factors, such as placental mosaicism or prior co-twin demise. The current study was designed to examine the behavior of mosaicism ratio (MR) in multifetal gestations. Multifetal cfDNA specimens with positive results for trisomies 21, 18, or 13 and confirmed diagnostic outcomes were compiled to examine MR of the aneuploid chromosome based on the number of affected fetuses/placentas. A second multifetal cohort was assembled to analyze the MR of the Y chromosome in cases with at least one male fetus. For aneuploid cases, the average MR of affected singletons (used as a biological proxy for two affected twins) was significantly higher than the average MR for twins in which one fetus was affected. The average MR of the aneuploid chromosome for one affected twin was 52%, 42%, and 48% of that of singleton gestations for trisomy 21, 18, and 13 cases, respectively. MR cutoffs of 0.7 for trisomy 21, and 0.5 for trisomies 18 and 13 may help predict whether one versus both twins are affected with aneuploidy when clinical concern arises. For male cases, the Y MR of XX/XY gestations was 48% of the Y MR for XY/XY gestations. Using a Y MR cutoff of 0.8 allowed determination of XX/XY versus XY/XY gestations with 92.3-94.9% accuracy. Based on the data presented, MR may have utility in the analysis and interpretation of cfDNA data from multifetal gestations.

Entities:  

Year:  2021        PMID: 33711042      PMCID: PMC7954340          DOI: 10.1371/journal.pone.0248467

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  8 in total

1.  Fetal fraction estimate in twin pregnancies using directed cell-free DNA analysis.

Authors:  Craig A Struble; Argyro Syngelaki; Arnold Oliphant; Ken Song; Kypros H Nicolaides
Journal:  Fetal Diagn Ther       Date:  2013-12-07       Impact factor: 2.587

2.  The hidden mortality of monochorionic twin pregnancies.

Authors:  N J Sebire; R J Snijders; K Hughes; W Sepulveda; K H Nicolaides
Journal:  Br J Obstet Gynaecol       Date:  1997-10

3.  Determination of fetal DNA fraction from the plasma of pregnant women using sequence read counts.

Authors:  Sung K Kim; Gregory Hannum; Jennifer Geis; John Tynan; Grant Hogg; Chen Zhao; Taylor J Jensen; Amin R Mazloom; Paul Oeth; Mathias Ehrich; Dirk van den Boom; Cosmin Deciu
Journal:  Prenat Diagn       Date:  2015-06-03       Impact factor: 3.050

4.  Fetal sex determination in twin pregnancies using cell free fetal DNA analysis.

Authors:  Miguel Milan; Emilia Mateu; David Blesa; Monica Clemente-Ciscar; Carlos Simon
Journal:  Prenat Diagn       Date:  2018-04-23       Impact factor: 3.050

5.  Genome-wide cfDNA screening: clinical laboratory experience with the first 10,000 cases.

Authors:  Mathias Ehrich; John Tynan; Amin Mazloom; Eyad Almasri; Ron McCullough; Theresa Boomer; Daniel Grosu; Jason Chibuk
Journal:  Genet Med       Date:  2017-06-15       Impact factor: 8.822

6.  Fetal sex determination in twin pregnancies using non-invasive prenatal testing.

Authors:  Darine Villela; Huiwen Che; Marijke Van Ghelue; Luc Dehaspe; Nathalie Brison; Kris Van Den Bogaert; Koen Devriendt; Liesbeth Lewi; Baran Bayindir; Joris Robert Vermeesch
Journal:  NPJ Genom Med       Date:  2019-07-04       Impact factor: 8.617

7.  High-throughput massively parallel sequencing for fetal aneuploidy detection from maternal plasma.

Authors:  Taylor J Jensen; Tricia Zwiefelhofer; Roger C Tim; Željko Džakula; Sung K Kim; Amin R Mazloom; Zhanyang Zhu; John Tynan; Tim Lu; Graham McLennan; Glenn E Palomaki; Jacob A Canick; Paul Oeth; Cosmin Deciu; Dirk van den Boom; Mathias Ehrich
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

8.  Impact of mosaicism ratio on positive predictive value of cfDNA screening.

Authors:  Jill M Rafalko; Samantha Caldwell; John Tynan; Eyad Almasri; Vivian Weinblatt; Ron McCullough
Journal:  Prenat Diagn       Date:  2020-11-25       Impact factor: 3.050

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.